Studies have shown the ability of NMN to elevate systemic levels of NAD+ in humans and ameliorate many of the diseases of old age. In a new study on dogs, NMN was shown to be safe and to have similar efficacy as in humans.
Dog and human NAD+ levels both decline with age
Dogs have the same problem as humans in that their NAD+ levels decline with age in various critical organs, such as the heart, pancreas, adipose tissue, skeletal muscle, liver, skin, and brain. Supplementing with NMN has been shown to not only raise systemic NAD+ levels but increase overall healthspan and possibly lifespan as well.
Oral NMN was established as safe, even at higher levels
Part of the study evaluated whether high levels of NMN caused any subacute toxicity in beagle dogs being fed NMN, but even at high levels:
“administrating 1340 mg/d NMN in beagle dogs only results in mild increases in creatinine and uric acid, while other biomarkers remain unchanged.” (1)
“Taken together, our data indicates that high-dose and short-term oral administration of NMN has mild or minimal deleterious effects.” (1)
Oral NMN shown to dramatically raise NAD+ levels in dogs
10 dogs aged 4 years old were divided into two groups: a placebo group gavaged twice per day with 10 ml water and a second group gavaged twice per day with 10 ml NMN for a total of 14 days.
Serum was evaluated for liver and kidney function, insulin and blood lipids. Analysis showed that NMN had a dramatic effect on NAD+ levels.
“Our data showed that NAD+ in liver was dramatically increased, suggesting that oral administration of NMN efficiently boosts NAD+ in tissue.” (1)
“Taken together, our data demonstrate that oral gavage of NMN substantially elevates NAD+ in tissue with no significant side effects on liver and kidney.” (1)
NMN administration also lowered lipid and insulin levels
The study also showed that oral NMN administration had beneficial effects on lowering lipid and insulin levels. In fact, when using higher levels of oral NMN, these improvements were shown within just one week.